Lilly raises outlook for third time this year as Zepbound sales soar

Reported by MarketWatch · Published 29 Oct 2026, 7:19 PM MYT (1 hr ago)

Image: MarketWatch

The GLP-1 drug continues to dominate the market for prescription weight-loss drugs in the U.S.

Source & full coverage: this summary is aggregated from MarketWatch, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at MarketWatch →

Lilly raises outlook for third time this year as Zepbound sales soar

Summary

More in Markets

Inflation surges, PCE shows. Fed pause on rate hikes unlikely to last long with prices still rising.

Economy grows at fastest pace in more than a year, GDP shows, and shows little sign of slowing.

Caterpillar’s stock heads for worst day in 7 years — and what that means for the Dow

It’s the strangest job market the U.S. has ever seen. The low-hire, low-fire economy turns 3 years old.

You can’t rely on the S&P 500 as much as you may think

The Fed held off on a rate hike. Today’s GDP and inflation reports could make waiting harder.